D-0829-2021 Class II Terminated

Recalled by Direct Rx — Dawsonville, GA

FDA drug recall D-0829-2021 was initiated by Direct Rx on Sep 14, 2021 and is designated Class II. Reason for recall: CGMP deviations: Gaps in the quality system in the Quality Control microbiology laboratory. The recall status is terminated (terminated Oct 22, 2021). Affected quantity: 2 bottles.

Recall details

Product Type
Drugs
Report Date
Sep 29, 2021
Initiation Date
Sep 14, 2021
Termination Date
Oct 22, 2021
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
2 bottles

Product description

Zonisamide 100 mg Capsules, 30-count bottles, Packaged and Distributed By: Direct Rx Dawsonville, GA 30534 Mfg. For Glenmark Pharmaceuticals Inc., USA Mahwah, NJ 07430, NDC 61919-0775-30

Reason for recall

CGMP deviations: Gaps in the quality system in the Quality Control microbiology laboratory.

Distribution pattern

FL only

Code information

Lot #: 17JU2118 Exp. 5/31/23

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0829-2021
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0829-2021. Report a data issue: hello@regdatalab.com.